Patents by Inventor Tim Beissert

Tim Beissert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNA REPLICON FOR REPROGRAMMING SOMATIC CELLS
    Publication number: 20200277627
    Abstract: The present invention embraces a RNA replicon that can be replicated by a replicase of alphavirus origin and comprises an open reading frame encoding a reprogramming factor. Such RNA replicons are useful for expressing a reprogramming factor in a cell, in particular a somatic cell. Cells engineered to express such reprogramming factors are useful in cell transplantation therapies.
    Type: Application
    Filed: September 11, 2018
    Publication date: September 3, 2020
    Inventors: Marco Alexander POLEGANOV, Mario PERKOVIC, Ugur SAHIN, Tim BEISSERT
  • Method for cellular RNA expression
    Patent number: 10729784
    Abstract: The present invention relates to expressing RNA in cells and, in particular, enhancing viability of cells in which RNA is to be expressed. Specifically, the present invention provides methods for expressing RNA in cells comprising the steps of preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells. Thus, preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells allows repetitive transfer of RNA into the cells.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: August 4, 2020
    Assignees: TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSM, BIONTECH RNA PHARMACEUTICALS GMBH
    Inventors: Ugur Sahin, Tim Beissert, Marco Poleganov, Stephanie Herz, Lars Koste
  • Agents for treatment of claudin expressing cancer diseases
    Patent number: 10717780
    Abstract: The present invention provides binding agents that contain n binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: July 21, 2020
    Assignees: BioNTech AG, Ganymed Pharmaceuticals GmbH, TRON—Translationale Onkologic an der Universitätsmedzin der Johannes Gutenberg-Universität Mainz gemcinnützige GmbH
    Inventors: Ugur Sahin, Ozlem Türeci, Christiane Stadler, Julia Holland, Hayat Bähr-Mahmud, Tim Beissert, Laura Plum, Fabrice Le Gall, Arne Jendretzki, Markus Fiedler
  • METHOD FOR CELLULAR RNA EXPRESSION
    Publication number: 20190269793
    Abstract: The present invention relates to expressing RNA in cells and, in particular, enhancing viability of cells in which RNA is to be expressed. Specifically, the present invention provides methods for expressing RNA in cells comprising the steps of preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells. Thus, preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells allows repetitive transfer of RNA into the cells.
    Type: Application
    Filed: January 11, 2019
    Publication date: September 5, 2019
    Inventors: Ugur Sahin, Tim Beissert, Marco Poleganov, Stephanie Herz, Lars Koste
  • USE OF RNA FOR REPROGRAMMING SOMATIC CELLS
    Publication number: 20190194623
    Abstract: The present invention provides methods for de-differentiating somatic cells into stem-like cells without generating embryos or fetuses. More specifically, the present invention provides methods for effecting the de-differentiation of somatic cells to cells having stem cell characteristics, in particular pluripotency, by introducing RNA encoding factors inducing the de-differentiation of somatic cells into the somatic cells and culturing the somatic cells allowing the cells to de-differentiate.
    Type: Application
    Filed: January 17, 2019
    Publication date: June 27, 2019
    Inventors: Ugur Sahin, Marco Poleganov, Tim Beissert
  • 3'-UTR Sequences for Stabilization of RNA
    Publication number: 20190071682
    Abstract: The present invention relates to stabilization of RNA, in particular mRNA, and an increase in mRNA translation. The present invention particularly relates to a modification of RNA, in particular in vitro-transcribed RNA, resulting in increased transcript stability and/or translation efficiency. According to the invention, it was demonstrated that certain sequences in the 3?-untranslated region (UTR) of an RNA molecule improve stability and translation efficiency.
    Type: Application
    Filed: October 5, 2016
    Publication date: March 7, 2019
    Inventors: Alexandra Orlandini Von Niessen, Stephanie Fesser, Britta Vallazza, Tim Beissert, Andreas Kuhn, Ugur Sahin, Marco Alexander Poleganov
  • Agents for Treatment of Claudin Expressing Cancer Diseases
    Publication number: 20190055311
    Abstract: The present invention provides binding agents that contain n binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
    Type: Application
    Filed: August 30, 2018
    Publication date: February 21, 2019
    Inventors: Ugur Sahin, Ozlem Türeci, Christiane Stadler, Julia Holland, Hayat Bähr-Mahmud, Tim Beissert, Laura Plum, Fabrice Le Gall, Arne Jendretzki, Markus Fiedler
  • Method for cellular RNA expression
    Patent number: 10207009
    Abstract: The present invention relates to expressing RNA in cells and, in particular, enhancing viability of cells in which RNA is to be expressed. Specifically, the present invention provides methods for expressing RNA in cells comprising the steps of preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells. Thus, preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells allows repetitive transfer of RNA into the cells.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: February 19, 2019
    Assignees: TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSM, BIONTECH RNA PHARMACEUTICALS GMBH
    Inventors: Ugur Sahin, Tim Beissert, Marco Poleganov, Stephanie Herz, Lars Koste
  • Agents for treatment of claudin expressing cancer diseases
    Patent number: 10093736
    Abstract: The present invention provides binding agents that contain a binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: October 9, 2018
    Assignees: BIONTECH AG, TRON GGMBH, UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ, GANYMED PHARMACEUTICALS AG
    Inventors: Ugur Sahin, Ozlem Tureci, Christiane Stadler, Julia Holland, Hayat Bahr-Mahmud, Tim Beissert, Laura Plum, Fabrice Le Gall, Arne Jendretzki, Markus Fiedler
  • USE OF RNA FOR REPROGRAMMING SOMATIC CELLS
    Publication number: 20170218342
    Abstract: The present invention provides methods for de-differentiating somatic cells into stem-like cells without generating embryos or fetuses. More specifically, the present invention provides methods for effecting the de-differentiation of somatic cells to cells having stem cell characteristics, in particular pluripotency, by introducing RNA encoding factors inducing the de-differentiation of somatic cells into the somatic cells and culturing the somatic cells allowing the cells to de-differentiate.
    Type: Application
    Filed: April 12, 2017
    Publication date: August 3, 2017
    Inventors: Ugur Sahin, Marco Poleganov, Tim Beissert
  • Agents for Treatment of Claudin Expressing Cancer Diseases
    Publication number: 20160272711
    Abstract: The present invention provides binding agents that contain a binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
    Type: Application
    Filed: November 12, 2013
    Publication date: September 22, 2016
    Inventors: Ugur Sahin, Ozlem Tureci, Christiane Stadler, Julia Holland, Hayat Bahr-Mahmud, Tim Beissert, Laura Plum, Fabrice Le Gall, Arne Jendretzki, Markus Fiedler
  • USE OF RNA FOR REPROGRAMMING SOMATIC CELLS
    Publication number: 20160122721
    Abstract: The present invention provides methods for de-differentiating somatic cells into stem-like cells without generating embryos or fetuses. More specifically, the present invention provides methods for effecting the de-differentiation of somatic cells to cells having stem cell characteristics, in particular pluripotency, by introducing RNA encoding factors inducing the de-differentiation of somatic cells into the somatic cells and culturing the somatic cells allowing the cells to de-differentiate.
    Type: Application
    Filed: November 5, 2015
    Publication date: May 5, 2016
    Inventors: Ugur SAHIN, Marco POLEGANOV, Tim BEISSERT
  • METHOD FOR CELLULAR RNA EXPRESSION
    Publication number: 20150314018
    Abstract: The present invention relates to expressing RNA in cells and, in particular, enhancing viability of cells in which RNA is to be expressed. Specifically, the present invention provides methods for expressing RNA in cells comprising the steps of preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells. Thus, preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells allows repetitive transfer of RNA into the cells.
    Type: Application
    Filed: May 7, 2015
    Publication date: November 5, 2015
    Inventors: Ugur Sahin, Tim Beissert, Marco Poleganov, Stephanie Herz, Lars Koste
  • Method for Cellular RNA Expression
    Publication number: 20140030808
    Abstract: The present invention relates to enhancing RNA expression in a cell such as a cell transfected with RNA by reducing the activity of RNA-dependent protein kinase (PKR). Thus, the present invention provides methods for expressing RNA in a cell comprising the step of reducing the activity of RNA-dependent protein kinase (PKR) in the cell. Reducing the activity of RNA-dependent protein kinase (PKR) in the cell increases the stability of RNA and/or increases the expression of RNA in the cell.
    Type: Application
    Filed: December 2, 2011
    Publication date: January 30, 2014
    Applicants: BIONTECH AG, Universitatsmedizin der Johannes Gutenberg- Universitat Mainz, Translationale Onkologie an der Universitatsmediz- in der JGU Mainz gGmbH (TRON)
    Inventors: Ugur Sahin, Tim Beissert, Marco Poleganov, Stephanie Herz
  • USE OF RNA FOR REPROGRAMMING SOMATIC CELLS
    Publication number: 20110065103
    Abstract: The present invention provides methods for de-differentiating somatic cells into stem-like cells without generating embryos or fetuses. More specifically, the present invention provides methods for effecting the de-differentiation of somatic cells to cells having stem cell characteristics, in particular pluripotency, by introducing RNA encoding factors inducing the de-differentiation of somatic cells into the somatic cells and culturing the somatic cells allowing the cells to de-differentiate.
    Type: Application
    Filed: December 12, 2008
    Publication date: March 17, 2011
    Inventors: Ugur Sahin, Marco Poleganov, Tim Beissert